EP0931263A1 - Screeningsferfahren für nebenwirkungen von antikonzeptionsmitteln oder östrogen und/oder progesteron ersatz- oder zusatzmitteln - Google Patents
Screeningsferfahren für nebenwirkungen von antikonzeptionsmitteln oder östrogen und/oder progesteron ersatz- oder zusatzmittelnInfo
- Publication number
- EP0931263A1 EP0931263A1 EP96930447A EP96930447A EP0931263A1 EP 0931263 A1 EP0931263 A1 EP 0931263A1 EP 96930447 A EP96930447 A EP 96930447A EP 96930447 A EP96930447 A EP 96930447A EP 0931263 A1 EP0931263 A1 EP 0931263A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acute phase
- compound
- composition
- increase
- sex steroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000000694 effects Effects 0.000 title claims abstract description 42
- 238000012216 screening Methods 0.000 title claims abstract description 16
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims description 11
- 239000000262 estrogen Substances 0.000 title claims description 11
- 229940011871 estrogen Drugs 0.000 title claims description 10
- 229960003387 progesterone Drugs 0.000 title description 3
- 239000000186 progesterone Substances 0.000 title description 3
- 230000001380 anti-conceptive effect Effects 0.000 title description 2
- 239000013589 supplement Substances 0.000 title description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 claims abstract description 71
- 108010062271 Acute-Phase Proteins Proteins 0.000 claims abstract description 71
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 239000003163 gonadal steroid hormone Substances 0.000 claims abstract description 34
- 239000003539 oral contraceptive agent Substances 0.000 claims abstract description 30
- 229940127234 oral contraceptive Drugs 0.000 claims abstract description 29
- 108010075016 Ceruloplasmin Proteins 0.000 claims abstract description 22
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 22
- 238000003556 assay Methods 0.000 claims abstract description 17
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 13
- 230000002503 metabolic effect Effects 0.000 claims abstract description 13
- 230000015271 coagulation Effects 0.000 claims abstract description 7
- 238000005345 coagulation Methods 0.000 claims abstract description 7
- 230000007717 exclusion Effects 0.000 claims abstract description 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 48
- 102100032752 C-reactive protein Human genes 0.000 claims description 48
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 22
- 102100036537 von Willebrand factor Human genes 0.000 claims description 22
- 239000000583 progesterone congener Substances 0.000 claims description 16
- 229960001134 von willebrand factor Drugs 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 15
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 12
- 230000001076 estrogenic effect Effects 0.000 claims description 12
- 206010048998 Acute phase reaction Diseases 0.000 claims description 11
- 108010049003 Fibrinogen Proteins 0.000 claims description 11
- 102000008946 Fibrinogen Human genes 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 229940012952 fibrinogen Drugs 0.000 claims description 11
- 230000001154 acute effect Effects 0.000 claims description 9
- 230000001747 exhibiting effect Effects 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 8
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 claims description 6
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000000451 tissue damage Effects 0.000 claims description 6
- 231100000827 tissue damage Toxicity 0.000 claims description 6
- 102000004506 Blood Proteins Human genes 0.000 claims description 5
- 108010017384 Blood Proteins Proteins 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 5
- 239000003862 glucocorticoid Substances 0.000 claims description 5
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 5
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 5
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims description 4
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 230000023597 hemostasis Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 102000013566 Plasminogen Human genes 0.000 claims description 3
- 108010051456 Plasminogen Proteins 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 108010089414 Anaphylatoxins Proteins 0.000 claims description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- APTGJECXMIKIET-WOSSHHRXSA-N Norethindrone enanthate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 APTGJECXMIKIET-WOSSHHRXSA-N 0.000 claims description 2
- 102000004140 Oncostatin M Human genes 0.000 claims description 2
- 108090000630 Oncostatin M Proteins 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 239000000367 immunologic factor Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 2
- 229960002082 norethindrone enanthate Drugs 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- -1 1 and 6 Proteins 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 102000023732 binding proteins Human genes 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 21
- 229960004976 desogestrel Drugs 0.000 description 19
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000006187 pill Substances 0.000 description 14
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 13
- 229960005352 gestodene Drugs 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 229960004400 levonorgestrel Drugs 0.000 description 10
- 229960000417 norgestimate Drugs 0.000 description 10
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 10
- 229940030225 antihemorrhagics Drugs 0.000 description 8
- 230000000025 haemostatic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000001548 androgenic effect Effects 0.000 description 6
- 108010024337 cortisol binding globulin Proteins 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 206010020112 Hirsutism Diseases 0.000 description 3
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 3
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000004658 acute-phase response Effects 0.000 description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 229960005471 androstenedione Drugs 0.000 description 3
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 229960001910 lynestrenol Drugs 0.000 description 3
- 230000004066 metabolic change Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000757 progestagenic effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- 102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 108091008361 cortisol binding proteins Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WNSDZLZVSSOOCA-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WNSDZLZVSSOOCA-WOMZHKBXSA-N 0.000 description 1
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 102100027619 Histidine-rich glycoprotein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108010044853 histidine-rich proteins Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108010093564 inter-alpha-inhibitor Proteins 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Definitions
- Preparations with sex steroids have been developed for birth control, supplementation e.g. when women enter the menopause, replacement when women have had hysterectomies. Alternatively they are used for sex- change processes and growth inhibition for tall boys and girls.
- the preparations used in the field of anticonception have in recent history been adapted with regard to both dosage and type of compounds. The reason was the recognition that besides the targeted action of the sex steroids in anticonception, additional effects occurred in the first generation pills and increased occurrence of cardiovascular disease in these groups was documented in epidemiological surveys .
- the dose of the estrogenic component was identified as an important determinant and was reduced gradually with time. Up till recently, epidemiology supported these adaptations of the third generation in showing reductions in cardiovascular side effects. Newer formulations with lower dosages are being evaluated for future use. Up till recently, epidemiology supported these adaptations in showing reductions in cardiovascular side effects.
- progestagen-only pills were not considered extensively because current evidence suggested that changes are small even by sensitive indicators of lipid and carbohydrate metabolism and components of hemostasis. Furthermore there are insufficient epidemiologic data to determine whether the progestagen-only pills influence the risk of cardiovascular diseases.” They further state that the progestagen component is mainly responsible for the effect of OCs (oral contraceptives) on carbohydrate metabolism and that the effects on hemostasis are conceivably estrogen mediated because they have not been demonstrated in progestagen-only preparations.
- OCs oral contraceptives
- Oral contraceptives most often contain both an estrogenic and a prostagenic compound.
- the mechanisms involved in metabolic changes to date were considered to reflect estrogenic metabolic effects of the estrogen component and, depending upon the compound, intrinsic estrogenic, androgenic or anti-estrogenic properties of the progestagenic component. Firstly with this in mind the dosage of estrogen was lowered.
- a set of modern, new prostagenic compounds including desogestrel, gestodene and norgestimate were in recent years introduced and they represent the so-called third generation Ocs.
- the newer progestins were designed to minimize the adverse effects (e.g., acne, hirsuitism, nausea, carbohydrate and lipid metabolism changes) observed with older Ocs, while maintaining efficacy and good menstrual cycle control.
- Desogestrel, norgestimate, and gestodene have minimal amounts of androgenicity and antiestrogenic potential as described in Ann-Pharmacother. 1995 Jul-Aug; 29(7 ⁇ 8): 736-42. This article reviews and compares the newer progestins desogestrel, norgestimate, and gestodene with regard to chemistry, pharmacokinetics, efficacy, and tolerability .
- any of the combination OC products that contain these progestins may be prescribed for women intolerant of older agents" or to first-time users of OCs.
- the newer progestins appear to be efficacious and offer similar cycle control, improved safety and tolerability profiles, and comparable price with the older agents.
- SHBG sex-hormone-binding globulin
- CBG cortisol-binding globulin
- DHEAS dihydroepiandrosterone sulfate
- the DHEAS concentration decreased less with the 20 micrograms EE + desogestrel formulation compared with either 30 micrograms EE + desogesterel or norgestimate-containing formulations (20% vs. 5%) .
- Concentrations of SHBG and CBG increased significantly in all four groups (average 263 + / ⁇ 119% and +/- 26%, respectively); CBG increased less in women taking 20 micrograms EE + desogestrel (about 75%) than in the other formulations (about 100%).
- the four modern, low-dose OCs tested had similar impacts on endogenous androgen metabolism, yielding significant decreases in testosterone, dihydrotestosterone, androstenedione, and DHEAS.
- SHBG sex hormone binding globulin
- CBG cortisol-binding globulin
- DHEAS dihydroepiandrosterone sulfate
- the subject invention is thus directed at a method for screening for negative side effects of a sex steroid compound or composition by assessing the level of a marker selected from a group of proteins or complexes of proteins hitherto never associated with a sex steroid compound or known negative side effects thereof in a subject after said subject has been dosed with said compound or composition.
- a sex steroid composition is a composition useful for the applications described above in particular as contraceptive for reproduction and in hormone replacement or supplementing therapy.
- a sex steroid composition comprises an oestrogenic and/or progestogenic compound or combination thereof.
- a method according to the invention can be applied within the first one to six months of intake of the preparation in order to assess whether the subject is sensitive to the preparation.
- APR acute phase reactants
- the acute phase of the inflammatory response refers to a wide range of physiological changes initiated immediately after infection or physical trauma.
- the ensuing cascade of mediators induces activation proliferation and altered behavior and changes in the biosynthetic capacities of a variety of target cells and tissues.
- An important aspect of the acute phase response is the radically altered biosynthetic profile of the liver.
- Hepatic acute phase reactants comprise the following proteins: complement proteins :C2. C3.
- C4 binding protein proteinase inhibitors: ⁇ l-antitrypsin, ⁇ l-antichymotrypsin, ⁇ 2- antiplasmin, Heparin co actor II, metal binding proteins:ha toglobulin.
- a number of other reactants also exist such as the major reactant Secretory Phospholipase A2 (sPLA2), ferritin, retinol binding protein, and coagulation related proteins i.e. tissue plasminogen activator and plasminogen.
- sPLA2 major reactant Secretory Phospholipase A2
- ferritin ferritin
- retinol binding protein retinol binding protein
- coagulation related proteins i.e. tissue plasminogen activator and plasminogen.
- proteins have also been proposed to belong to the group of APRs but remain to be confirmed. This group comprises angitensinogen, kininogen, kininogenase , fibronectin, prothrombin, Factor VIII, heparin cofactor II.
- Some of the hepatic reactants have also been illustrated to be produced extra hepatically e.g. SAA.
- the acute phase reactants vary in degree in which they are or can be activated.
- an acute phase reactant is defined as a reactant that can vary in concentration by 25% or more in the first 7 days of inflammation or following tissue damage.
- the major acute phase reactants can be produced up to 1000 fold their basic level. Ceruloplasmin and C3 exhibit about 50% increase.
- the response is known to be initiated and coordinated by a large number of inflammatory mediators, which include cytokines, anaphylatoxins and glucocorticoids.
- cytokines include cytokines, anaphylatoxins and glucocorticoids.
- Several hormones specifically regulate the transcripton of human APRs include interleukin 1 , interleukin 6, tumor necrosis factor, transforming growth factor ⁇ , interferon gamma, glucocorticoids and effector molecules comprising interleukin 2, oncostatin M, ciliary neurotrophic factor and retinoic acid.
- interleukin 1 and tumor necrosis factor induce APR synthesis in the liver and stabilisation of mRNA for positive APRs occurs by cytokines and glucocorticoids. Mackiewicz A., Ganapathi M.K.
- CRP Creprivation protein
- pro-inflammatory component itself, and in increasing tissue trauma effects makes an increase in this component undesirable for persons defective or weak in control mechanisms of trauma reactions such as individuals with hereditary defects in the anticoagulation system (deficiencies in antithrombin III, protein S and Factor V Leiden).
- an increase in CRP not only marks acute phase effects but also adds directly to the risk of venous thrombosis.
- the increase in the vascular von Willebrand factor and in factor VIII itself are also considered undesirable in view of the previously already described association between elevated levels of these components and the risk of venous thrombosis (Br-Heart-J. 1995 Dec; 74(6): 580-3).
- vWF seems to mediate platelet aggregation and adhesion to the vascular endothelium. It further states because the release of vWF is increased when endothelial cells are damaged, vWF has been proposed as an indicator of endothelial disturbance or dysfunction.
- the availability of such an index of endothelial dysfunction is postulated as having clinical value, because measurement of such a marker can be a non-invasive way of assisting in diagnosis or as an indicator of disease progression.
- the known association between vWF, thrombogenesis, and atherosclerotic vascular disease also suggests that high concentrations of vWF may be an indirect indicator of atherosclerosis and/or thrombosis.
- APRs acute phase reactants
- the group of APRs exhibiting more than 100 fold incremental change during an acute phase reaction forms an extremely suited group of proteins for carrying out a test according to the invention due to the high degree of sensitivity that can be achieved. This is in contrast to other proteins belonging to the group of APRs in general like ceruloplasmin, von Willebrand factor, Factor VIII or fibrinogen which exhibit much smaller increments.
- the invention comprises a method for screening for negative side effects of a sex steroid compound or composition in a subject, by carrying out an assay on the subject or on a sample derived from the subject determining whether an increase of the compound or composition on the level of an acute phase reactant or a metabolic derivative thereof has occcurred since applying the compound or composition to the subject, said acute phase reactant being selected from the group consisting of positive APRs with the exclusion of ceruloplasmin and the coagulation/thrombosis associated factors described above.
- a suitable group of embodiments of the above type comprises a method using an APR selected from metal binding proteins with the exclusion of ceruloplasmin. Another suitable group is that of proteinase inhibitors.
- a preferred embodiment of the claimed invention is defined as ollows: A method for screening for negative side effects of a sex steroid compound or composition in a subject, by carrying out an assay on the subject or on a sample derived from the subject determining whether an increase of the compound or composition on the level of an acute phase reactant or a metabolic derivative thereof has occcurred since applying the compound or composition to the subject, said acute phase reactant being selected from the group consisting of APRs defined as being capable of exhibiting more than 100 fold increment within 7 days after tissue damage or inflammation, preferably more than 200 fold, whereby an increase in the level of the acute phase reactant is indicative of negative side effects.
- the preferred markers to be used in the invention belong to the group of APRs known to be capable of exhibiting up to 1000 fold increase during an acute phase reaction Markers belonging to. Additionally preferred markers according to the invention belong to the group of APRs exhibiting a low or slightly variable basic level thus enabling good quantification of a disturbance in this level.
- This group comprises the proteins serum amyloid A (SAA), serum amyloid P (SAP), C-reactive Protein (CRP) and Secretory Phospholipase A2 (sPLA2) as disclosed by D.M. Steel and A.S. Whitehead in Immunology Today 1994; 15: 81-88 by Kushner et al as mentioned elsewhere in this description.
- the sample to be analysed in any of the embodiments of a method according to the invention can be a blood sample or any other sample suitable for assessing levels of plasma proteins as is common knowledge for a person skilled in the art.
- the method according to the invention can be carried out in an in vitro system or in an in vivo system. Both animal and human test sytems can be used. CRP cannot be tested in a rat system however as it is absent in rats. Alternative APP proteins of the type described can however be used in a rat model. SAP is the rat homologue of CRP. CRP is one of the preferred markers for use in humans .
- the detection methods to be used will depend on the marker to be analysed .
- Numerous assays are already known for determining the amounts of such proteins.
- the CRP can be determined using the CRP assay disclosed in the WHO Expert Committee on Biological Standardisation (37th Report. World Health Organ Tech. Rep. Ser. 1987; 760: 21-22 and New Engl . J. Med. 1994; 331: 417-424).
- the SAA assay can be carried out as disclosed by J. Wilkins, J.R. Gallimore, G.A. Tennent et al in Clin Chem 1994; 40: 1284-1290.
- SAP is described by R.L. Meek, S. Urieli-Shovall and E.P.
- the screening will additionally involve determination of the level of a haemostatic factor, said haemostatic factor also belonging to the group of APRs.
- haemostatic factor such factors are fibrinogen (Thompson et al cited above) , von Willebrand Factor (B.E. Pottinger, R.C. Read, E.M. Paleolog, P.G. Higgins and J.D. Pearson in Thromb. Res. 1 89; 53: 3 ⁇ 7-394), Tissue Plasminogen Activator (t-PA)(J.H. Jansson, B. Norberg, T.K. Nilsson in Clin.
- Plasminogen Activator Inhibitor (PAI-I) (J.H. Jansson, B. Norberg, T.K. Nilsson in Clin. Chem 1989; 35: 1544-1545), plasminogen (I. Juhan-Vague, M.C. Alessi, P. Joly, X. Thirion, P. Vague, P.J. Declerck, A. Serradimigni and D. Collen in Arterisclerosis 1989; 9 - 362-367) and ⁇ 2 -anti ⁇ lasmin (Steel et al as cited above).
- PAI-I Plasminogen Activator Inhibitor
- a method for determining an increase in von Willebrand factor in combination with any of the preferred embodiments described above for the method according to the invention with the first APR falls within the preferred scope of the invention.
- Determination of an increase of an APR from the group defined as capable of exhibiting more than 100 fold increase within the first 7 days after tissue damage or upon inflammation provides a suitable embodiment of the aforementioned screening method with 2 APRs.
- Screening assays for haemostatic factors are described in large detail in the prior art. Specifically reference is made to the ECAT Assay Procedures, A manual of Laboratory techniques, European Concerted Action on Thrombosis and Disabilities of the Commission of the European Communities, edited by J. Jespersen, R.M. Bertina and F. Haverkate. The information regarding hamostatic factor assays of the factors described in the previous sentence is hereby incorporated by reference. Numerous alternatives exist and will be readily apparent to a person skilled in the art.
- An alternative embodiment of the invention comprises an in vitro method for screening for negative side effects of a sex steroid compound or composition in a subject, by carrying out an assay on a sample that has been exposed to the compound or composition determining whether an increase of the compound or composition on the level of an acute phase reactant modulator or a metabolic derivative thereof has occcurred since applying the compound or composition.
- the modulator being suitably selected from the group consisting of biological response modifiers.
- biological modifiers comprise the modifiers mentioned earlier contributing to induction of APRs such as cytokines, interleukins etc. Specifically the enhancers of CRP are preferred. We hypothesize that estrogens appear to have a stimulatory effect on a package of acute phase proteins.
- the negative side effects to be combatted are those of increased risk of cardiovascular disease such as thrombosis.
- the negative side effects are those correlated to increase in one or more acute phase reactants.
- the screening can occur using any of the methods according to the invention as disclosed above.
- the compounds thus screened can be novel compounds or can be found amongst known compounds. Combination of the compounds can lead to a sex steroid preparation as safe as the third generation pills or better. It can also lead to alternative formulations at least as good as the known second generation pills.
- the determining factor is that the new formulation comprising either a novel compound or a combination of novel compounds or a novel combination of known compounds exhibits less increase in an APR than a third generation pill preferably less than a second generation pill when these are compared.
- a sex steroid preparation according to the invention will not result in an increase of an APR as can be determined using a method according to the invention.
- Such alternative forms of providing medication are as such known for other fields of medicine and for some sex steroid preparations.
- Examples of known intrauterine devices releasing a sex steroid preparation are the Progestasert which releases progesterone at a rate of 65 micrograms per day and the LNG-20 which releases 20 micrograms of levonorgestrel per day.
- the Norplant system employs silastic tubing permeable to steroid molecules to provide stable circulating levels of levonorgestrel .
- Depot-medroxyprogesterone acetate (Depo Provera) is given in the form of an injection as is norethindrone enanthate.
- Transdermal application of oestrogen is also known.
- the volunteers were randomized (open label) to the use of two different 0C preparations with an equal dose of ethinylestradiol (30 ug) , but different type and dose of progesteron, being either 75 ug gestodene (GTD-EE) or 150 ug desogestrel (DSG-EE).
- C-reactive protein was measured with an enzyme-immuno-assay , using horseradish peroxidase labelled polyclonal antibodies against CRP ( Dako, Copenhagen, Denmark) as catching and tagging antibody in a manner known per se.
- CRP standard serum (Beh ⁇ ngwerke, Marburg, Germany) was - --
- Plasma CRP levels were measured by an enzyme immunoassay (ELISA) .
- the microtitration plates were coated with 100 ⁇ l Rabbit-anti-human CRP (DAKO, Denmark) in coating buffer (1:8000) and incubated overnight at 4°C. The wells were washed three times with 0,1# PBS-Tween-20 .and ImM Na 2 EDTA.
- the plasma samples diluted 1:1000 (Hamilton, MicroLab 1000) in PBS-Tween containing 3% polyethylene glycol 6000 were added in duplicate to the coated wells. The plates were incubated for two hours at room temperature, the wells were rewashed three times and 100 ⁇ l peroxidase- conjugated rabbit-anti-human CRP was added for one hour at room temperature.
- C-reactive protein was measured with an enzyme-immuno-assay , using horseradish peroxidase labelled polyclonal antibodies against CRP ( Dako, Copenhagen, Denmark) as catching and tagging antibody.
- CRP standard serum (Behringwerke, Marburg, Germany) was used to standardize the results (see detailed procedure according to Example I) .
- Observations CRP-values Pretreatment 6 weeks
- the pretreatment values in both groups are not statistical significant different.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL1996/000350 WO1998010293A1 (en) | 1996-09-06 | 1996-09-06 | Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0931263A1 true EP0931263A1 (de) | 1999-07-28 |
Family
ID=19865999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96930447A Withdrawn EP0931263A1 (de) | 1996-09-06 | 1996-09-06 | Screeningsferfahren für nebenwirkungen von antikonzeptionsmitteln oder östrogen und/oder progesteron ersatz- oder zusatzmitteln |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0931263A1 (de) |
JP (1) | JP2002505736A (de) |
AU (1) | AU733553B2 (de) |
CA (1) | CA2265516C (de) |
WO (1) | WO1998010293A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001094951A2 (en) * | 2000-06-08 | 2001-12-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-reactive protein induced inflammation |
KR101061562B1 (ko) | 2008-08-28 | 2011-09-06 | 대한민국 | 비스테로이드성 항염제의 부작용을 예측하는 방법 |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
-
1996
- 1996-09-06 WO PCT/NL1996/000350 patent/WO1998010293A1/en not_active Application Discontinuation
- 1996-09-06 EP EP96930447A patent/EP0931263A1/de not_active Withdrawn
- 1996-09-06 CA CA002265516A patent/CA2265516C/en not_active Expired - Fee Related
- 1996-09-06 AU AU69475/96A patent/AU733553B2/en not_active Ceased
- 1996-09-06 JP JP51250898A patent/JP2002505736A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9810293A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2265516C (en) | 2004-02-03 |
AU733553B2 (en) | 2001-05-17 |
AU6947596A (en) | 1998-03-26 |
WO1998010293A1 (en) | 1998-03-12 |
CA2265516A1 (en) | 1998-03-12 |
JP2002505736A (ja) | 2002-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU733553B2 (en) | Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements | |
Soldin et al. | Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry | |
BALLARD et al. | A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man | |
Helleday et al. | Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency | |
Vexiau et al. | Androgen excess in women with acne alone compared with women with acne and/or hirsutism. | |
Lejeune-Lenain et al. | Control of circadian and episodic variations of adrenal androgens secretion in man | |
Hill et al. | Circulating levels of pregnanolone isomers during the third trimester of human pregnancy | |
Brody et al. | Pharmacokinetics of three bioequivalent norethindrone/mestranol-50ug and three norethindrone/ethinyl estradiol-35ug oc formulations: Are “low-dose” pills really lower? | |
Pařízek et al. | Neuroactive pregnanolone isomers during pregnancy | |
ILLINGWORTH et al. | Progesterone receptor of the human myometrium | |
Mattsson et al. | Lipid composition of serum lipoproteins in relation to gonadal hormones during the normal menstrual cycle | |
Darne et al. | Diurnal variation of plasma and saliva oestrogen, progesterone, cortisol and plasma dehydroepiandrosterone sulphate in late pregnancy | |
Magnani et al. | In vitro fertilization: Do short-term changes in estrogen levels produce increased fibrinolysis? | |
US20020110523A1 (en) | Methods for screening or monitoring the risk of cardiovascular disease relating to sex steroid compound or composition intake and methods for screening sex steroid compound | |
Prelević et al. | Effects of a Iow-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome | |
Kjær et al. | Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene | |
Schulman et al. | Mineralocorticoid and glucocorticoid receptor steroid binding and localization in colonic cells | |
Chu et al. | Plasma α1-acid glycoprotein levels in pregnancy | |
Gruschke et al. | Validity of radioimmunological methods for determining free testosterone in serum | |
Nordborg et al. | von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis. | |
Dušková et al. | Steroid diagnostics of 21st century in the light of their new roles and analytical tools | |
Pereira et al. | Lipid peroxidation and nitric oxide inactivation in postmenopausal women | |
Kasid et al. | Interaction of progestins with steroid receptors in human uterus | |
BROTHERTON et al. | Some aspects of the effect of cyproterone acetate on levels of other steroid hormones in man | |
Briggs et al. | Oral contraceptives and plasma protein metabolism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990301 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060401 |